Physician profile
Kerri Gray
NPI 1700880184
$16,168.95
in general payments reported to CMS, 2019-2025
48 companies · $3,140 in 2025
The $3,140 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $1,529 · 2021: $2,628 · 2022: $1,422 · 2023: $2,779 · 2024: $3,098 · 2025: $3,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,872 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,871.79 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,893.29 | 2019-2025 | Farxiga, Tezspire, Breztri |
| Abbvie INC. | $2,055.98 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,299.65 | 2019-2025 | Trintellix |
| Pfizer INC. | $841.75 | 2019-2025 | |
| Novo Nordisk INC | $825.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $733.46 | 2019-2020 | |
| Lilly USA, LLC | $657.16 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $653.65 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Glaxosmithkline, LLC. | $602.32 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Supernus Pharmaceuticals, INC. | $601.96 | 2021-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $502.43 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $414.72 | 2020-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $372.62 | 2019-2025 | Rexulti |
| Gilead Sciences, INC. | $371.11 | 2019-2021 | |
| Daiichi Sankyo INC. | $367.83 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.